Abstract
A once-daily tablet formulation (Isentress® HD; Isentress® 600mg) of the integrase strand transfer inhibitor raltegravir is now available for the treatment of HIV-1 infection. The 600mg tablet has improved bioavailability versus the existing twice-daily 400mg tablet (due, at least in part, to differences in tablet dissolution) and the recommended dosage is 1200mg (i.e. two 600mg tablets) once daily. In combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve adults, once-daily raltegravir 1200mg provided virological suppression non-inferior to that seen with twice-daily raltegravir 400mg over 48 and 96weeks in the phase3 ONCEMRK trial. The once-daily raltegravir regimen was also generally well tolerated in this study, displaying a tolerability profile similar to that of the twice-daily regimen. The once-daily tablet simplifies and improves the convenience of raltegravir regimens, although its impact on adherence has yet to be determined. Thus, once-daily raltegravir tablets are a convenient alternative to twice-daily raltegravir tablets for the treatment of HIV-1, further expanding the therapeutic options available to meet the diverse needs of this patient population.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call